Impact Proteomics
Molecular Diagnostics · Bioinformatics
Overview
Impact Proteomics is an immune profiling biotech company that leverages a unique and unbiased platform to enable antigen identification.
Key facts
These are the key facts about Impact Proteomics on Alion as of Nov 13, 2026. Impact Proteomics is headquartered in Pittsburgh, United States. The latest round is Convertible Note of $50k, announced in 2024.
- Headquarters
- Pittsburgh, United StatesAlion company profile, updated Nov 8, 2026
- Total raised
- $50kSum of 1 equity round Alion knows
- Latest round
- Convertible Note · $50k · Aug 6, 2024SEC Form D filing · sec.gov
Official records
Funding and backers
Total raised
$50k
4 rounds on record
Latest round
$50k
Convertible Note · Aug 2024 · 2 yr ago
Grants
$1.2M
2 grants · CORDIS
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 6, 2024
Raised a round Convertible Note $50k · SEC Form D
Apr 15, 2021
Won a grant $1000k · CORDIS
Feb 7, 2020
Took on debt financing $200k · SEC Form D
Jan 1, 2019
Won a grant $225k · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Aug 2024 | $50k | — | SEC Form D |
| Grant | Apr 2021 | $1000k | — | CORDIS |
| Debt Financing | Feb 2020 | $200k | — | SEC Form D |
| Grant | Jan 2019 | $225k | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | Impact Proteomics, LLC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jeffrey WhitmoreExecutive Officer, DirectorSEC Form D
Jonathan MindenExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Teiko is a CLIA-certified clinical laboratory serving both clinical trials and physicians, with CRO services for trials and high-complexity…
Protai leverages proteomics and AI to accelerate drug discovery, enabling faster identification of novel therapeutic targets and biomarkers.
Discover the antibody reactome. Infinity Bio's MIPSA platform reveals past and ongoing immune responses across comprehensive human, viral…
SurgeCare leverages immune profiling and AI to reveal early immune signatures and drive better decisions in surgery, trauma, infection, and…
Making immune complexity predictable and actionable. ImmuNovus combines mechanistic models of the immune system with AI-assisted simulation…
Discover dynamic biomarkers beyond the genome. Our multi-omics services enable profiling of thousands of metabolites, lipids & proteins per…
People
Jeffrey Whitmore
Executive Officer, Director
Jonathan Minden
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Pittsburgh
United States
HQ
How to cite this page
Alion, "Impact Proteomics: key facts", as of Nov 13, 2026. https://alion.io/company/impact-proteomics
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0